Background and Objective: Graves' disease has been associated with an increased psychiatric morbidity. It is unclarified whether this relates to Graves' disease or chronic disease per se. The aim of our study was to estimate the prevalence of anxiety and depression symptoms in patients with Graves' disease compared to patients with another chronic thyroid disease, nodular goitre, and to investigate determinants of anxiety and depression in Graves' disease. Methods: 157 cross-sectionally sampled patients with Graves' disease, 17 newly diagnosed, 140 treated, and 251 controls with nodular goitre completed the Hospital Anxiety and Depression Scale (HADS). The differences in the mean HADS scores between the groups were analysed using multiple linear regression, controlling for socio-demographic variables. HADS scores were also analysed dichotomized: a score >10 indicating probable ‘anxiety'/probable ‘depression'. Determinants of anxiety and depression symptoms in Graves' disease were examined using multiple linear regression. Results: In Graves' disease levels of anxiety (p = 0.008) and depression (p = 0.014) were significantly higher than in controls. The prevalence of depression was 10% in Graves' disease versus 4% in nodular goitre (p = 0.038), anxiety was 18 versus 13% (p = 0.131). Symptoms of anxiety (p = 0.04) and depression (p = 0.01) increased with comorbidity. Anxiety symptoms increased with duration of Graves' disease (p = 0.04). Neither thyroid function nor autoantibody levels were associated with anxiety and depression symptoms. Conclusions: Anxiety and depression symptoms were more severe in Graves' disease than in nodular goitre. Symptoms were positively correlated to comorbidity and duration of Graves' disease but neither to thyroid function nor thyroid autoimmunity.

Keywords:
Graves’ disease, Depression, Anxiety, Quality of life, Nodular goitre
1.
Martin-Merino E, Ruigomez A, Johansson S, Wallander MA, Garcia-Rodriguez LA: Study of a cohort of patients newly diagnosed with depression in general practice: prevalence, incidence, comorbidity, and treatment patterns. Prim Care Companion J Clin Psychiatry 2010;12:PCC.
2.
Hall RC, Hall RC: Anxiety and endocrine disease. Semin Clin Neuropsychiatry 1999;4:72-83.
3.
Gold MS, Pottash AL, Extein I: Hypothyroidism and depression. Evidence from complete thyroid function evaluation. JAMA 1981;245:1919-1922.
4.
Radanovic-Grguric L, Filakovic P, Barkic J, Mandic N, Karner I, Smoje J: Depression in patients with thyroid dysfunction. Eur J Psychiatry 2003;17:133-144.
5.
Larisch R, Kley K, Nikolaus S, Sitte W, Franz M, Hautzel H, et al: Depression and anxiety in different thyroid function states. Horm Metab Res 2004;36:650-653.
6.
Thvilum M, Brandt F, Almind D, Christensen K, Brix TH, Hegedus L: Increased psychiatric morbidity before and after the diagnosis of hypothyroidism: a nationwide register study. Thyroid 2014;24:802-808.
7.
Brandt F, Thvilum M, Almind D, Christensen K, Green A, Hegedus L, et al: Hyperthyroidism and psychiatric morbidity: evidence from a Danish nationwide register study. Eur J Endocrinol 2014;170:341-348.
8.
Elberling TV, Rasmussen AK, Feldt-Rasmussen U, Hording M, Perrild H, Waldemar G: Impaired health-related quality of life in Graves' disease. A prospective study. Eur J Endocrinol 2004;151:549-555.
9.
Gulseren S, Gulseren L, Hekimsoy Z, Cetinay P, Ozen C, Tokatlioglu B: Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction. Arch Med Res 2006;37:133-139.
10.
Trzepacz PT, McCue M, Klein I, Levey GS, Greenhouse J: A psychiatric and neuropsychological study of patients with untreated Graves' disease. Gen Hosp Psychiatry 1988;10:49-55.
11.
Stern RA, Robinson B, Thorner AR, Arruda JE, Prohaska ML, Prange AJ Jr: A survey study of neuropsychiatric complaints in patients with Graves' disease. J Neuropsychiatry Clin Neurosci 1996;8:181-185.
12.
Iacovides A, Fountoulakis KN, Grammaticos P, Ierodiakonou C: Difference in symptom profile between generalized anxiety disorder and anxiety secondary to hyperthyroidism. Int J Psychiatry Med 2000;30:71-81.
13.
Thomsen AF, Kvist TK, Andersen PK, Kessing LV: Increased risk of affective disorder following hospitalisation with hyperthyroidism - a register-based study. Eur J Endocrinol 2005;152:535-543.
14.
Vogel A, Elberling TV, Hording M, Dock J, Rasmussen AK, Feldt-Rasmussen U, et al: Affective symptoms and cognitive functions in the acute phase of Graves' thyrotoxicosis. Psychoneuroendocrinology 2007;32:36-43.
15.
Kathol RG, Turner R, Delahunt J: Depression and anxiety associated with hyperthyroidism: response to antithyroid therapy. Psychosomatics 1986;27:501-505.
16.
Jackson IM: The thyroid axis and depression. Thyroid 1998;8:951-956.
17.
Placidi GPA, Boldrini M, Patronelli A, Fiore E, Chiovato L, Perugi G, et al: Prevalence of psychiatric disorders in thyroid-diseased patients. Neuropsychobiology 1998;38:222-225.
18.
Fahrenfort JJ, Wilterdink AM, van der Veen EA: Long-term residual complaints and psychosocial sequelae after remission of hyperthyroidism. Psychoneuroendocrinology 2000;25:201-211.
19.
Bunevicius R, Velickiene D, Prange AJ: Mood and anxiety disorders in women with treated hyperthyroidism and ophthalmopathy caused by Graves' disease. Gen Hosp Psychiatry 2005;27:133-139.
20.
Perrild H, Hansen JM, Arnung K, Olsen PZ, Danielsen U: Intellectual impairment after hyperthyroidism. Acta Endocrinol (Copenh) 1986;112:185-191.
21.
Bommer M, Eversmann T, Pickardt R, Leonhardt A, Naber D: Psychopathological and neuropsychological symptoms in patients with subclinical and remitted hyperthyroidism. Klin Wochenschr 1990;68:552-558.
22.
Carta MG, Loviselli A, Hardoy MC, Massa S, Cadeddu M, Sardu C, et al: The link between thyroid autoimmunity (antithyroid peroxidase autoantibodies) with anxiety and mood disorders in the community: a field of interest for public health in the future. BMC Psychiatry 2004;4:25.
23.
Pop VJ, Maartens LH, Leusink G, van Son MJ, Knottnerus AA, Ward AM, et al: Are autoimmune thyroid dysfunction and depression related? J Clin Endocrinol Metab 1998;83:3194-3197.
24.
Engum A, Bjoro T, Mykletun A, Dahl AA: Thyroid autoimmunity, depression and anxiety; are there any connections? An epidemiological study of a large population. J Psychosom Res 2005;59:263-268.
25.
Ghanem AA, Amr MA, Araafa LF: Graves' ophthalmopathy and psychoendocrinopathies. Middle East Afr J Ophthalmol 2010;17:169-174.
26.
Brandt F, Green A, Hegedus L, Brix TH: A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol 2011;165:491-497.
27.
Brandt F, Almind D, Christensen K, Green A, Brix TH, Hegedus L: Excess mortality in hyperthyroidism: the influence of preexisting comorbidity and genetic confounding: a Danish nationwide register-based cohort study of twins and singletons. J Clin Endocrinol Metab 2012;97:4123-4129.
28.
Brandt F, Thvilum M, Almind D, Christensen K, Green A, Hegedus L, et al: Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study. PLoS One 2013;8:e66711.
29.
Brandt F, Thvilum M, Almind D, Christensen K, Green A, Hegedus L, et al: Graves' disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study. Thyroid 2013;23:408-413.
30.
Watt T, Bjorner JB, Groenvold M, Rasmussen AK, Bonnema SJ, Hegedus L, et al: Establishing construct validity for the thyroid-specific patient reported outcome measure (ThyPRO): an initial examination. Qual Life Res 2009;18:483-496.
31.
Zigmond AS, Snaith RP: The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361-370.
32.
Herrmann C: International experiences with the Hospital Anxiety and Depression Scale - a review of validation data and clinical results. J Psychosom Res 1997;42:17-41.
33.
Snaith RP: The Hospital Anxiety and Depression Scale. Health Qual Life Outcomes 2003;1:29.
34.
DeCoster J, Iselin A, Gallucci M: A conceptual and empirical examination of justifications for dichotomization. Psychol Methods 2009;14:349-366.
35.
Watt T, Hegedus L, Groenvold M, Bjorner JB, Rasmussen AK, Bonnema SJ, et al: Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO. Eur J Endocrinol 2010;162:161-167.
36.
Suwalska A, Lacka K, Lojko D, Rybakowski JK: Quality of life, depressive symptoms and anxiety in hyperthyroid patients. Rocz Akad Med Bialymst 2005;50(suppl 1):61-63.
37.
Rockel M, Teuber J, Schmidt R, Kaumeier S, Hafner H, Usadel KH: Correlation of ‘latent hyperthyroidism' with psychological and somatic changes (in German). Klin Wochenschr 1987;65:264-273.
38.
Trzepacz PT, Klein I, Roberts M, Greenhouse J, Levey GS: Graves' disease: an analysis of thyroid hormone levels and hyperthyroid signs and symptoms. Am J Med 1989;87:558-561.
39.
Trzepacz PT, McCue M, Klein I, Greenhouse J, Levey GS: Psychiatric and neuropsychological response to propranolol in Graves' disease. Biol Psychiatry 1988;23:678-688.
40.
Fukao A, Takamatsu J, Murakami Y, Sakane S, Miyauchi A, Kuma K, et al: The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug-treated patients with Graves' disease. Clin Endocrinol (Oxf) 2003;58:550-555.
© 2014 European Thyroid Association Published by S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.